Skip to main content
LRMR
NASDAQ Life Sciences

Larimar Therapeutics to Initiate Rolling BLA Submission for Nomlabofusp in June 2026

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$4.1
Mkt Cap
$425.92M
52W Low
$1.73
52W High
$6.42
52W Position info
137% above low
Off High info
36% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

LRMR has more than doubled off its 52-week low of $1.73 on light trading volume (0.2× avg).

Summary

Larimar Therapeutics announced plans to begin a rolling BLA submission for nomlabofusp in June 2026 and expects topline open-label study data in Q2 2026, alongside a strong cash position extending into Q2 2027.


Key Events · Product Development and Regulatory · LRMR

  • Rolling BLA Submission Initiated

    Larimar Therapeutics plans to begin a rolling Biologics License Application (BLA) submission for nomlabofusp in June 2026, seeking accelerated approval for Friedreich's ataxia, with final modules expected in the second half of 2026.

  • Topline Open-Label Study Data Expected

    Topline data from the open-label study, intended to support the BLA submission, is anticipated in the second quarter of 2026.

  • Strong Cash Position and Runway

    The company reported $200.4 million in cash, cash equivalents, and marketable securities as of March 31, 2026, providing a projected cash runway into the second quarter of 2027.

  • Global Phase 3 Study Planned

    Dosing of the first patient in the global confirmatory Phase 3 study for nomlabofusp is expected to initiate in mid-2026.


Analysis · LRMR · Life Sciences

This 8-K provides a critical update on the regulatory path for nomlabofusp, Larimar's lead candidate for Friedreich's ataxia. The company plans to initiate a rolling Biologics License Application (BLA) submission for accelerated approval in June 2026, starting with nonclinical and clinical modules. This sets a clear near-term timeline for a major regulatory milestone. Additionally, topline data from the open-label study, which will support the BLA, is expected in Q2 2026, providing another significant catalyst. The company also reported a strong cash position of $200.4 million, extending its runway into Q2 2027, which is crucial for funding ongoing development and the planned global Phase 3 study.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LRMR was trading at $4.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $425.9M. The 52-week trading range was $1.73 to $6.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LRMR - Latest Insights

LRMR
Nov 12, 2026, 6:02 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $2.73
Real-time Price: $2.98 info
Change: +$0.250 (+9%) info
Market Cap: $313.726M info
LRMR
Nov 09, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.53
Real-time Price: $2.98 info
Change: +$0.450 (+18%) info
Market Cap: $313.726M info
LRMR
Aug 04, 2026, 7:12 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $3.95
Real-time Price: $2.98 info
Change: -$0.970 (-25%) info
Market Cap: $313.726M info
LRMR
Aug 04, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.80
Real-time Price: $2.98 info
Change: -$0.820 (-22%) info
Market Cap: $313.726M info
LRMR
Aug 04, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.81
Real-time Price: $2.98 info
Change: -$0.8345 (-22%) info
Market Cap: $313.726M info